A phase II multicenter study of bortezomib, thalidomide, peghilated liposomal doxorubicin, dexamethasone (thadd-v) in patients affected by relapsed-refractory multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 25 May 2011
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 25 May 2011 New trial record